Methods and compositions for oral administration of protein and peptide therapeutic agents
The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.
1. An oral pharmaceutical composition, comprising an oil having particulate matter suspended therein, wherein the composition is not an emulsion and the particulate matter comprises:
a. a polysaccharide comprising at least one branched polysaccharide selected from the group consisting of amylopectin, starch, glycogen and combinations thereof, wherein the polysaccharide is in non-covalent association with silica nanoparticles having a hydrophobic surface, wherein the size of the silica nanoparticles is between 1-100 nanometers and wherein the weight of the branched polysaccharide is at least twice that of the silica nanoparticles; and
b. a protein or peptide having therapeutic activity, non-covalently associated with said silica nanoparticles and the polysaccharide.
2. The pharmaceutical composition of claim 1 , wherein said composition is anhydrous.
3. The pharmaceutical composition of claim 1 , wherein said size of said silica nanoparticles is between 5-30 nanometers.
4. The pharmaceutical composition of claim 1 , wherein said hydrophobic surface of said silica nanoparticles comprises hydrocarbon moieties.
5. The pharmaceutical composition of claim 1 , further comprising a structural protein selected from the group consisting of elastin, collagen, keratin, fibrinogen and combinations thereof.
6. The pharmaceutical composition of claim 1 , further comprising an amino acid selected from the group consisting of arginine, lysine, glutamic acid, aspartic acid, histidine and combinations thereof.
7. The pharmaceutical composition of claim 1 , wherein said oil comprises a mixture of oils.
8. The pharmaceutical composition of claim 1 , wherein said oil comprises a mixture of oils selected from natural vegetable oils and synthetic oils.
9. The pharmaceutical composition of claim 1 , wherein said composition further comprises an antioxidant.
10. The pharmaceutical composition of claim 1 , wherein said protein or peptide is selected from a group consisting of: erythropoietin, pituitary growth hormone, glatiramer acetate, apolipoprotein A-1-mimetic peptide, monoclonal antibody against the protein CD20, calcitonin, a tumor necrosis factor (TNF) protein, interferon-alpha, interferon-beta, interferon-gamma, DNase, RNase, and combinations thereof.
11. The pharmaceutical composition of claim 1 , wherein the weight of said particulate matter is not more than 25% of the volume of said pharmaceutical composition.